Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sight Sciences (SGHT) Cash & Equivalents (2020 - 2025)

Sight Sciences (SGHT) has 6 years of Cash & Equivalents data on record, last reported at $92.0 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 23.59% year-over-year to $92.0 million; the TTM value through Dec 2025 reached $92.0 million, down 23.59%, while the annual FY2025 figure was $92.0 million, 23.59% down from the prior year.
  • Cash & Equivalents reached $92.0 million in Q4 2025 per SGHT's latest filing, roughly flat from $92.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $271.5 million in Q3 2021 and bottomed at $35.6 million in Q2 2021.
  • Average Cash & Equivalents over 5 years is $152.4 million, with a median of $138.1 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: surged 518.74% in 2022, then dropped 29.86% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $260.7 million in 2021, then fell by 29.03% to $185.0 million in 2022, then fell by 25.34% to $138.1 million in 2023, then fell by 12.87% to $120.4 million in 2024, then fell by 23.59% to $92.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $92.0 million in Q4 2025, $92.4 million in Q3 2025, and $101.5 million in Q2 2025.